Secondary endpoint Secondary analyses for QoL and data were summarized using the mITT population. Participants’ baseline scores were used to determine the effect of xylometazoline hydrochloride 0.1% on additional QoL factors. The changes from baseline in mean additional QoL scores were analyzed each day using a Student’s paired t-test, and p-values were assessed to a significance level of α = 0.05. Median post-treatment scores were presented for each day of treatment through day 7 or until data were no longer provided due to nasal symptom resolution, whichever came first.